Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

Provider of private equity investment services globally. The company's investment services include direct and fund of fund investments in the middle-market sector across all investment stages, enabling early access to investment opportunities and an ability to quickly add value to portfolio companies.

Developer of a predictive analytics platform designed to translate medical data into intelligent predictions to support and optimize clinical decisions. The company's platform supports maternal and neonatal applications to evaluate, optimize, and personalize medical strategies for the care of newborns, enabling medical practitioners to improve and personalize health care in early life and avoid long-term complications.

Developer and manufacturer of medical devices intended to manage cardiovascular health. The company offers products that provide personalized and precise management of cardiovascular risks, hypertension and peripheral artery disease (PAD) as well as screenings for vital parameters to identify risk factors that can lead to cardiovascular disease, thereby helping professionals measure what matters, prevent cardiovascular events and improve diagnosis and therapy efficiently.

Qureight is an imaging analytics company. It also aims to develop a new improved and streamlined version of its analytical platform – harnessing the ability of AI and advanced processing tools to gain new insights into respiratory diseases such as Idiopathic Pulmonary Fibrosis (IPF) and lung cancer.

Pharmacelera is a company that applies accurate Quantum-Mechanics (QM) algorithms, Machine Learning (ML) and High-Performance Computing (HPC) to mine an unexploited chemical space and propose molecular candidates that have higher chances to become a drug. The patented computational technology derives from more than 25 years of research at the University of Barcelona and it has been validated in scientific peer-reviewed publications and benchmarking studies performed by our users and customers.

Biorce is an innovating HealthAI startup committed to transforming drug development through the use of artificial intelligence.

Developer of biomedical imaging technology designed to assist in pre-clinical and clinical trial applications. The company utilizes the photoacoustic effect to visualize and quantify anatomical, functional, and molecular information, in vivo, and deep tissue, and in real-time provides real-time visualization of anatomical, functional, and molecular information in living tissue, enabling doctors to detect tumors and inflammatory diseases without having to resort to invasive procedures.

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

MedicubeX aims to revolutionize preventive healthcare by building a network of autonomous self-measurement and telehealth eHealth Stations. We are the most advanced health kiosk and the first one in the Nordics. The eHealth Station offers regular clinical-grade medical check-ups for everyone regardless of location.